title: Schisantherin B ameliorates Aβ1-42-induced cognitive decline via restoration of GLT-1 in a mouse model of Alzheimer's disease.
abstract: Accumulation of amyloid beta (Aβ) peptide and hyperphosphorylated tau protein has been proposed to play roles in neural destruction which induce Alzheimer's disease (AD) progresses, glutamate transporter type 1 (GLT-1) and Glycogen synthase kinase3β (GSK3β) may be the pathological links between Aβ and tau pathology. Schisantherin B (STB) is one bioactive of lignans isolated from Schisandra chinensis (Turcz.) Baill which has been commonly used as a traditional herbal medicine for thousands of years. This paper was designed to investigate the effects of STB on improving the cognitive function and neurodegeneration in the mouse model of Alzheimer's disease induced by Aβ1-42, and its possible mechanism were Glutamate transporter GLT-1, tau and GSK3β. It was found that successive intracerebroventricular (ICV) administration of STB (0.15mg/kg) for 5days significantly attenuated Aβ1-42-induced learning and memory impairment as measured by the Locomotor activity test, Y-maze test and Morris water maze test. Furthermore, STB at a dose of 0.15mg/kg restored the activities of GLT-1 and GSK3β while decreasing the levels of hyperphosphorylated tau protein in the hippocampus and cerebral cortex. The results suggested that STB might protect against cognitive deficits and neurodegeneration induced by Aβ1-42in mice by regulating the GLT-1 restoration as well as the capacity of GSK3β.
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
authors.forename: Mengjie
authors.initials: M
authors.lastname: Xu
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
authors.forename: Shutong
authors.initials: S
authors.lastname: Wan
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
authors.forename: Tingxu
authors.initials: T
authors.lastname: Yan
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
authors.forename: Jingdi
authors.initials: J
authors.lastname: Cao
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China.
authors.forename: Lidan
authors.initials: L
authors.lastname: Wu
authors.affiliation: The Engineering Laboratory of National and Local Union of Quality Control for Traditional Chinese Medicine, School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shengyang 110016, China.
authors.forename: Kaishun
authors.initials: K
authors.lastname: Bi
authors.affiliation: Key Laboratory of Active Components of Chinese Medicine Screening and Evaluation, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang 110016, China. Electronic address: jiayingsyphu@126.com.
authors.forename: Ying
authors.initials: Y
authors.lastname: Jia
mesh_terms: D000544:Alzheimer Disease / Q000139:chemically induced / Q000150:complications; D016229:Amyloid beta-Peptides / Q000633:toxicity*; D000704:Analysis of Variance; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003072:Cognition Disorders / Q000139:chemically induced* / Q000188:drug therapy*; D034242:Cyclooctanes / Q000627:therapeutic use; D004149:Dioxoles / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D027342:Excitatory Amino Acid Transporter 2 / Q000378:metabolism*; D000071679:Glycogen Synthase Kinase 3 beta / Q000378:metabolism; D017705:Lignans / Q000627:therapeutic use*; D008124:Locomotion / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D010446:Peptide Fragments / Q000633:toxicity*; D011083:Polycyclic Compounds / Q000627:therapeutic use*; D013997:Time Factors; D016875:tau Proteins / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D034242:Cyclooctanes; D004149:Dioxoles; D027342:Excitatory Amino Acid Transporter 2; D017705:Lignans; D010446:Peptide Fragments; D011083:Polycyclic Compounds; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; C082090:schisantherin B; D000071679:Glycogen Synthase Kinase 3 beta
keywords: Alzheimer's disease; Aβ(1–42); GLT-1; GSK3β; Schisantherin B; tau